Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Total Current Liabilities
All obligations due within one year.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 46.5% from a year ago
Total current liabilities stood at $13.46M at the end of Q1 FY2026, up 46.5% from a year earlier and down 26.6% from the prior quarter. Over 3 fiscal years it compounded at +41.5% a year.
Context
- Total current liabilities amounted to 9.2% of total assets at the end of Q1 FY2026, up 3.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +46.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 18.34M USD
- Year-over-year change
- +58.5%
- 4-year CAGR
- +42.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.34M | +58.5% |
| FY2024 | 2024-12-31 | 11.58M | +197.2% |
| FY2023 | 2023-12-31 | 3.9M | -39.8% |
| FY2022 | 2022-12-31 | 6.48M | +47.1% |
| FY2021 | 2021-12-31 | 4.4M | — |
Total Current Liabilities vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's Mar 2026 total current liabilities of $13.46M is the 10th highest of the 11 companies compared; the peer median is $29.69M.
- Its year-over-year change of +46.5% is the 4th highest of 11, against a peer median of -0.7%.
- Total current liabilities amounts to 9.2% of total assets for ELDN, versus a peer median of 15.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $135.58M | +30.5% | +16.7% | 31.3% | |
| Mar 2026 | $59.74M | -31.1% | +1.6% | 31.0% | |
| Mar 2026 | $39.78M | -45.6% | -8.4% | 26.6% | |
| Mar 2026 | $33.37M | +53.4% | +29.1% | 12.5% | |
| Mar 2026 | $31.05M | +72.6% | +56.1% | 15.6% | |
| Mar 2026 | $28.33M | -5.6% | -15.4% | 7.2% | |
| Mar 2026 | $19.2M | +4.1% | +3.6% | 5.7% | |
| Mar 2026 | $17.45M | -56.6% | -28.5% | 8.0% | |
| Mar 2026 | $16.19M | -19.2% | -2.1% | 14.6% | |
| Mar 2026 | $13.46M | +46.5% | +41.5% | 9.2% | |
| Mar 2026 | $11.83M | +66.0% | -25.1% | 35.7% | |
| Peer median (excluding ELDN) | $29.69M | -0.7% | -0.3% | 15.1% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 84.83M | 56.41M | 4.61M | 20.55M | 22.81M |
| Short-term Investments | 0 | 0 | 46.49M | 119.63M | 110.53M |
| Net Receivables | 0 | 0 | 0 | 0 | 514K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 34K | 28K | 90K | 729K | 11K |
| Total Current Assets | 88.35M | 59.52M | 56.13M | 143.73M | 135.69M |
| Property, Plant & Equipment (Net) | 768K | 739K | 365K | 926K | 613K |
| Goodwill | 48.65M | 0 | 0 | 0 | 0 |
| Intangible Assets | 32.39M | 32.39M | 32.39M | 32.39M | 32.39M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 400K | 150K | 186K | 363K | 322K |
| Total Non-current Assets | 82.2M | 33.28M | 32.94M | 33.68M | 33.32M |
| Total Assets | 170.55M | 92.79M | 89.07M | 177.41M | 169.01M |
| Account Payables | 1.81M | 2.2M | 967K | 5.83M | 3.63M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.52M | 1.91M | 2M | 1.6M | 4.18M |
| Total Current Liabilities | 4.4M | 6.48M | 3.9M | 11.58M | 18.34M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.75M | 0 | 1.75M | 2.18M | 2.19M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 1.75M | 76.21M | 44.87M | 67.11M |
| Total Non-current Liabilities | 2.15M | 2.14M | 77.96M | 47.69M | 69.58M |
| Total Liabilities | 6.55M | 8.61M | 81.86M | 59.27M | 87.92M |
| Common Stock | 14K | 14K | 24K | 60K | 75K |
| Retained Earnings | (114.9M) | (202.87M) | (319.4M) | (355.59M) | (401.2M) |
| Accumulated OCI | 0 | 0 | 0 | 26K | 24K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 164M | 84.18M | 7.21M | 118.14M | 81.09M |
| Total Debt | 769K | 746K | 383K | 954K | 641K |
| Net Debt | (84.06M) | (55.66M) | (4.23M) | (19.6M) | (22.17M) |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.